Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NTRA

Natera Inc

Mar 18 • 04:00PM ET

146.28

Dollar change -2.97
Percentage change -1.99	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN GH TXG EXAS QGEN FLGT TWST MYGN CDNA BNGO

| Held by: VTI VB VXF VBK XBI IBB IWP ARKK VHT IWF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.53	Insider Own	5.30%	Shs Outstand	132.65M	Perf Week	4.47%
Market Cap	19.78B	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-10.52%	Shs Float	128.03M	Perf Month	-15.64%
Income	-190.43M	PEG	-	EPS next Q	-0.64	Inst Own	90.85%	Short Float	2.25%	Perf Quarter	-12.12%
Sales	1.70B	P/S	11.65	EPS this Y	-42.18%	Inst Trans	2.77%	Short Ratio	1.73	Perf Half Y	15.63%
Book/sh	9.01	P/B	16.23	EPS next Y	68.37%	ROA	-12.12%	Short Interest	2.88M	Perf Year	66.78%
Cash/sh	7.16	P/C	20.42	EPS next 5Y	-	ROE	-19.42%	52W Range	83.13 - 183.00	Perf YTD	-7.59%
Dividend Est.	-	P/FCF	285.60	EPS past 5Y	3.18%	ROI	-14.74%	52W High	-20.07%	Beta	1.79
Dividend TTM	-	Quick Ratio	3.87	Sales past 5Y	41.83%	Gross Margin	60.30%	52W Low	75.97%	ATR (14)	8.67
Dividend Ex-Date	-	Current Ratio	4.00	EPS Y/Y TTM	59.77%	Oper. Margin	-13.10%	RSI (14)	43.57	Volatility	4.30% 6.10%
Employees	4434	Debt/Eq	0.16	Sales Y/Y TTM	56.75%	Profit Margin	-11.22%	Recom	1.39	Target Price	199.40
Option/Short	Yes / Yes	LT Debt/Eq	0.08	EPS Q/Q	37.44%	Payout	-	Rel Volume	0.65	Prev Close	149.25
Sales Surprise	9.29%	EPS Surprise	-7.56%	Sales Q/Q	53.02%	Earnings	Feb 27 AMC	Avg Volume	1.67M	Price	146.28
SMA20	-2.78%	SMA50	-10.15%	SMA200	7.28%	Trades		Volume	1,082,794	Change	-1.99%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-13-25	Initiated	RBC Capital Mkts	Outperform	$251
Jan-23-25	Initiated	Barclays	Overweight	$200
Jun-03-24	Resumed	Jefferies	Buy	$142
Apr-08-24	Resumed	Craig Hallum	Buy	$117
Feb-20-24	Downgrade	Raymond James	Strong Buy → Outperform	$68 → $85
Dec-29-23	Reiterated	BTIG Research	Buy	$75 → $85
Dec-14-23	Initiated	Guggenheim	Buy	$70
Dec-13-23	Initiated	Wolfe Research	Outperform	$70
Nov-13-23	Upgrade	Raymond James	Outperform → Strong Buy	$68
Sep-28-23	Initiated	Bernstein	Mkt Perform	$48
Jul-05-23	Resumed	JP Morgan	Overweight	$85
May-05-23	Initiated	UBS	Buy	$76
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$58
Aug-25-22	Initiated	Credit Suisse	Outperform	$70
Apr-25-22	Initiated	Stephens	Overweight	$54
Mar-08-22	Initiated	Goldman	Buy	$90
Jan-06-22	Resumed	Piper Sandler	Overweight	$110
Oct-15-21	Resumed	Cowen	Outperform	$150
Jun-15-21	Initiated	Raymond James	Mkt Perform
May-25-21	Initiated	Wells Fargo	Overweight	$110

Show Previous Ratings

Mar-18-25 05:39AM	Is Natera (NTRA) the Best Biotech Stock According to Billionaires? (Insider Monkey)
Mar-11-25 03:07PM	Why Is Natera (NTRA) Stock Soaring Today (StockStory) +5.57%
Mar-10-25 08:00AM	Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer (Business Wire) -5.71%
Mar-07-25 09:30AM	Natera (NTRA) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
Mar-04-25 07:00AM	Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRD (Business Wire)
10:35AM	Loading…
Feb-28-25 10:35AM	Q4 2024 Natera Inc Earnings Call (Thomson Reuters StreetEvents)
02:37AM	Natera Inc (NTRA) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements (GuruFocus.com)
Feb-27-25 06:20PM	Natera (NTRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:53PM	Natera (NASDAQ:NTRA) Reports Bullish Q4, Guides for Strong Full-Year Sales (StockStory)
04:05PM	Natera Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 08:14AM	Natera (NTRA) Q4 Earnings: What To Expect (StockStory)
07:08AM	Natera Inc (NTRA) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Feb-25-25 06:00AM	Natera Announces Medicare Coverage of Signatera for Surveillance in Lung Cancer (Business Wire)
Feb-24-25 02:19PM	Natera, Inc. (NTRA): Among Top Stocks to Buy of Joe DiMennas Portfolio (Insider Monkey)
Feb-19-25 09:55AM	Natera (NTRA) Surged on Blowout Quarterly Results (Insider Monkey)
09:00AM	Loading…
Feb-18-25 09:00AM	Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025 (Business Wire)
Feb-14-25 03:47PM	Schrodinger Stock Scores IBD Rating Upgrade (Investor's Business Daily)
Feb-10-25 02:51PM	Trade Tracker: Amy Raskin trims Vertex, Natera & Kadant, buys CareDx and Impinj (CNBC TV)
07:00AM	NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell Carcinoma (Business Wire)
Feb-03-25 07:00AM	Natera Announces National Commercial Coverage for its Fetal RhD NIPT (Business Wire)
Jan-28-25 08:02AM	Heres Why Natera (NTRA) Surged in Q4 (Insider Monkey)
Jan-27-25 09:42AM	Natera reports new data from Phase III study of colorectal cancer detection test (Medical Device Network)
Jan-25-25 10:05AM	Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer (Business Wire)
Jan-21-25 06:05PM	Natera to Present New Data at the 2025 ASCO GI Symposium (Business Wire) +5.75%
04:03PM	Why Top 4% Guardant Health Surged To A 13-Month High And Topped A Profit-Taking Zone (Investor's Business Daily)
Jan-17-25 09:00AM	Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the Year (Business Wire) -6.02%
Jan-16-25 04:05PM	Exact Sciences Stock Drops 11% Over Four Days. 'What Is Going On?' (Investor's Business Daily)
Jan-15-25 07:00AM	Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer Detection (Business Wire)
Jan-12-25 07:20PM	Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024 (Business Wire)
Jan-09-25 08:15AM	Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings (Motley Fool)
09:00AM	Loading…
Jan-07-25 09:00AM	Natera to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Jan-03-25 02:03PM	Six IBD 50 Stocks Bear Gifts Even As Santa Claus Rally Fizzles (Investor's Business Daily)
Dec-17-24 09:35AM	Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
08:00AM	Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomics (Business Wire)
06:53AM	What Makes Natera (NTRA) a Top Stock Pick for Billionaire Stanley Druckenmiller? (Insider Monkey)
Dec-13-24 08:21AM	Natera enrolls 1st patients in SAGITTARIUS clinical trial in colon cancer (TipRanks)
Dec-12-24 08:00AM	Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer (Business Wire)
Dec-09-24 08:00AM	Natera and MyOme Announce Launch of iPRS for Breast Cancer Risk Assessment (Business Wire)
Dec-03-24 08:06AM	Strong Volume Growth Lifted Natera (NTRA) in Q3 (Insider Monkey)
Dec-02-24 02:40PM	Why Is Natera, Inc. (NTRA) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
08:00AM	Clinical Validation Study on Nateras Fetal RhD NIPT Published in Obstetrics and Gynecology (Business Wire)
08:00AM	Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & Gynecology (Business Wire)
05:00AM	Guardant awarded nearly $293M in false ad trial against Natera (MedTech Dive)
Nov-27-24 09:00AM	Natera Announces Medicare Coverage for Prospera in Single Lung Transplant Recipients (Business Wire)
Nov-25-24 07:57PM	Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium (Business Wire)
05:09PM	Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal (PR Newswire)
03:51PM	Natera Issues Statement on Guardant Health Litigation (Business Wire)
09:00AM	Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 RandD Leader of the Year (Business Wire)
09:00AM	Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year (Business Wire)
Nov-21-24 05:31PM	Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM (Business Wire)
Nov-14-24 09:09PM	Stanley Druckenmiller's Strategic Emphasis on Natera Inc in Q3 2024 (GuruFocus.com) -6.13%
Nov-13-24 10:25AM	Natera Stock Explodes 20% After Record-Breaking Q3--Is This Biotech Giant Just Getting Started? (GuruFocus.com) +19.13%
02:17AM	Natera Inc (NTRA) Q3 2024 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... (GuruFocus.com)
12:04AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Nov-12-24 06:30PM	Natera (NTRA) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:55PM	Natera (NTRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:48PM	Natera: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Third Quarter 2024 Financial Results (Business Wire)
07:00AM	Natera Announces Completion of Signatera Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer (Business Wire)
Nov-11-24 07:03AM	Natera Inc (NTRA) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-08-24 09:00AM	Natera to Participate in Upcoming Investor Conferences (Business Wire)
Nov-01-24 09:00AM	Natera to Report its Third Quarter 2024 Results on November 12, 2024 (Business Wire)
Oct-23-24 12:00PM	All You Need to Know About Natera (NTRA) Rating Upgrade to Strong Buy (Zacks)
Oct-22-24 09:00AM	Natera to Present New Renasight Data at ASN Kidney Week 2024 (Business Wire)
Oct-06-24 09:12AM	Natera Inc. (NTRA): Hedge Funds Are Bullish On This NASDAQ Stock Right Now (Insider Monkey)
Sep-23-24 04:06PM	Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase (Business Wire)
10:07AM	Should You Be Confident in the Growth Potential of Natera (NTRA)? (Insider Monkey)
Sep-16-24 07:13AM	ESMO 2024: Natera showcases chemotherapy prediction benefit of cDNA test (Medical Device Network)
05:17AM	Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO (Business Wire)
Sep-14-24 02:16PM	First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival (Business Wire)
Sep-11-24 05:59AM	Natera (NTRA) Continued its Incremental Strong Results (Insider Monkey)
Sep-09-24 11:42AM	DNA Testing Stock Taps AI Amid 85% Surge (Investor's Business Daily)
Sep-08-24 08:22PM	Natera to Present New Signatera Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival (Business Wire)
Sep-06-24 10:24AM	What Makes Natera (NTRA) an Investment Bet? (Insider Monkey)
Sep-03-24 02:37AM	Natera (NTRA) Rose After Revenues And Profit Margins Beat Estimates (Insider Monkey)
Aug-31-24 11:48AM	Billionaire Stan Druckenmiller Is Betting On Natera, Inc. (NTRA) (Insider Monkey)
Aug-29-24 02:07PM	The Committee's Comeback Kids: Trade Desk, Sweetgreen, Natera, Samsara, PayPal and Leidos (CNBC TV)
Aug-28-24 09:00AM	Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
Aug-27-24 03:19PM	PepsiCo, Inc. (PEP): Among Morgan Stanleys Highest Conviction Stocks (Insider Monkey)
03:16PM	Natera, Inc. (NTRA): Among Morgan Stanley's Highest Conviction Stocks (Insider Monkey)
Aug-17-24 01:01AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Aug-10-24 01:01AM	Decoding Natera Inc (NTRA): A Strategic SWOT Insight (GuruFocus.com)
Aug-09-24 09:46AM	Q2 2024 Natera Inc Earnings Call (Thomson Reuters StreetEvents) +6.38%
Aug-08-24 07:00PM	Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics (Zacks) +7.31%
05:19PM	Natera: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Natera Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-06-24 09:00AM	Natera to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-30-24 04:05PM	Natera to Report its Second Quarter 2024 Results on August 8, 2024 (Business Wire) -5.80%
Jul-29-24 10:53AM	Natera touts positive results for Merkel cell carcinoma surveillance test (Medical Device Network)
Jul-27-24 01:00AM	Insider Sale: CFO Michael Brophy Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Jul-26-24 08:00AM	New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma (Business Wire)
Jul-25-24 10:02AM	Natera (NTRA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-18-24 01:00AM	Insider Sale: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com) -8.35%
Jul-08-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in July 2024 (InvestorPlace)
Jul-03-24 08:53AM	Natera (NTRA) Soared After a 43% Increase In Revenue (Insider Monkey)
07:00AM	Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy (Business Wire)
05:30AM	Insider Sale: CEO and President Steven Chapman Sells 37,500 Shares of Natera Inc (NTRA) (GuruFocus.com)
Jun-27-24 07:00AM	Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer (Business Wire)
Jun-19-24 03:10AM	Insider Selling: CEO and President Steven Chapman Sells Shares of Natera Inc (NTRA) (GuruFocus.com)
Jun-17-24 07:00AM	Natera Launches Differentiated New Feature for Prospera Heart Test, Enhancing Detection of Rejection for Transplant Patients (Business Wire)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sheena Jonathan	Director	Mar 18 '25	Proposed Sale	145.90	17,840	2,602,856		Mar 18 05:18 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Mar 14 '25	Sale	147.70	50,000	7,385,249	2,365,415	Mar 14 09:35 PM
Marcus Gail Boxer	Director	Mar 12 '25	Option Exercise	7.86	4,000	31,440	13,704	Mar 14 09:35 PM
Marcus Gail Boxer	Director	Mar 12 '25	Sale	147.69	4,000	590,773	9,704	Mar 14 09:35 PM
MATTHEW RABINOWITZ	Director	Mar 14 '25	Proposed Sale	147.71	50,000	7,385,250		Mar 14 04:10 PM
Marcus Gail Boxer	Officer	Mar 12 '25	Proposed Sale	147.69	4,000	590,773		Mar 12 04:02 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Mar 05 '25	Sale	143.29	6,000	859,734	143,768	Mar 07 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Mar 05 '25	Sale	143.40	87,272	12,515,006	203,354	Mar 07 09:35 PM
SOLOMON MOSHKEVICH	Officer	Mar 05 '25	Proposed Sale	143.29	6,000	859,734		Mar 05 04:32 PM
STEVEN L CHAPMAN	Officer	Mar 05 '25	Proposed Sale	143.40	87,272	12,515,001		Mar 05 04:17 PM
Sheena Jonathan	CO-FOUNDER	Feb 26 '25	Sale	160.47	3,000	481,419	43,282	Feb 28 09:05 PM
Sheena Jonathan	CO-FOUNDER	Feb 26 '25	Sale	160.54	2,700	433,455	260,789	Feb 28 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Feb 06 '25	Sale	177.77	1,632	290,121	149,768	Feb 07 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Feb 06 '25	Sale	177.77	663	117,862	156,044	Feb 07 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Feb 03 '25	Sale	176.88	43,502	7,694,642	70,629	Feb 04 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 31 '25	Sale	173.05	400	69,220	114,131	Feb 04 09:45 PM
MICHAEL BURKES BROPHY	Officer	Feb 03 '25	Proposed Sale	176.92	43,902	7,767,142		Feb 03 04:22 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 29 '25	Sale	165.87	4,335	719,044	103,697	Jan 31 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 31 '25	Sale	176.60	1,886	333,068	101,811	Jan 31 09:45 PM
Sheena Jonathan	CO-FOUNDER	Jan 29 '25	Sale	165.87	1,054	174,827	260,103	Jan 31 09:35 PM
Sheena Jonathan	CO-FOUNDER	Jan 31 '25	Sale	176.60	163	28,786	259,940	Jan 31 09:35 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Jan 29 '25	Sale	165.87	6,003	995,716	2,383,177	Jan 31 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 29 '25	Sale	165.87	4,773	791,694	213,020	Jan 31 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 29 '25	Sale	165.87	5,201	862,688	135,483	Jan 31 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 29 '25	Sale	165.87	4,030	668,454	143,200	Jan 31 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 29 '25	Sale	165.87	13,685	2,269,928	253,944	Jan 31 09:35 PM
MICHAEL BURKES BROPHY	Officer	Jan 31 '25	Proposed Sale	176.27	1,886	332,445		Jan 31 04:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 27 '25	Sale	161.87	1,442	233,417	108,032	Jan 29 09:45 PM
MICHAEL BURKES BROPHY	Officer	Jan 27 '25	Proposed Sale	167.61	1,442	241,694		Jan 27 04:24 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 24 '25	Sale	171.98	946	162,689	109,474	Jan 24 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 23 '25	Sale	171.09	495	84,690	110,420	Jan 24 09:45 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Jan 22 '25	Sale	164.97	24,861	4,101,226	140,684	Jan 24 09:45 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Jan 22 '25	Sale	164.97	21,228	3,501,905	147,230	Jan 24 09:45 PM
MICHAEL BURKES BROPHY	Officer	Jan 24 '25	Proposed Sale	171.82	946	162,542		Jan 24 04:18 PM
Sheena Jonathan	CO-FOUNDER	Jan 22 '25	Sale	165.00	971	160,214	261,745	Jan 22 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 22 '25	Sale	164.97	22,039	3,635,685	217,793	Jan 22 09:45 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Jan 22 '25	Sale	164.97	78,553	12,958,585	267,629	Jan 22 09:45 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Jan 22 '25	Sale	164.97	25,931	4,277,735	109,665	Jan 22 09:45 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Jan 08 '25	Sale	175.30	6,223	1,090,901	199,804	Jan 10 09:35 PM
DANIEL RABINOWITZ	Officer	Jan 08 '25	Proposed Sale	170.40	6,223	1,060,399		Jan 08 04:23 PM
Sheena Jonathan	CO-FOUNDER	Jan 02 '25	Sale	159.55	3,000	478,645	44,782	Jan 03 09:55 PM
Sheena Jonathan	CO-FOUNDER	Jan 02 '25	Sale	159.44	2,700	430,480	254,372	Jan 03 09:55 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Dec 23 '24	Sale	159.60	669	106,773	114,142	Dec 26 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 23 '24	Sale	159.60	2,428	387,511	116,997	Dec 26 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 18 '24	Sale	167.24	3,000	501,713	46,282	Dec 20 09:05 PM
Sheena Jonathan	CO-FOUNDER	Dec 18 '24	Sale	167.27	2,700	451,625	257,072	Dec 20 09:05 PM
Sheena Jonathan	Director	Dec 18 '24	Proposed Sale	150.00	17,100	2,565,000		Dec 18 11:33 AM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Dec 13 '24	Sale	165.74	160,000	26,518,750	2,389,180	Dec 13 09:35 PM
MATTHEW RABINOWITZ	Director	Dec 13 '24	Proposed Sale	166.45	160,000	26,632,000		Dec 13 04:25 PM
Chapman Rowan E	Director	Dec 10 '24	Sale	170.24	1,767	300,808	6,202	Dec 11 09:05 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Dec 09 '24	Sale	166.59	4,858	809,312	114,912	Dec 11 09:05 PM
Chapman Rowan E	Officer	Dec 10 '24	Proposed Sale	170.24	1,767	300,808		Dec 10 03:08 PM
Moshkevich Solomon	Officer	Dec 09 '24	Proposed Sale	166.59	4,858	809,312		Dec 10 02:41 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Dec 05 '24	Option Exercise	5.40	68,496	369,556	2,549,180	Dec 09 04:05 PM
BOTHA ROELOF	Director	Dec 02 '24	Sale	169.12	87,473	14,793,563	1,224,787	Dec 04 05:13 PM
BV369 TRUST	Director	Dec 02 '24	Proposed Sale	169.12	87,473	14,793,565		Dec 02 04:58 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 25 '24	Sale	168.51	2,000	337,028	86,000	Nov 27 09:05 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 26 '24	Sale	164.17	2,000	328,348	84,000	Nov 27 09:05 PM
THE TINKERBELLE TRUST U/A DTD	Officer	Nov 26 '24	Proposed Sale	164.17	2,000	328,348		Nov 26 04:36 PM
THE TINKERBELLE TRUST U/A DTD	Officer	Nov 25 '24	Proposed Sale	168.51	2,000	337,028		Nov 25 06:37 PM
Marcus Gail Boxer	Director	Nov 19 '24	Sale	159.98	9,682	1,548,931	9,704	Nov 21 09:35 PM
Marcus Gail Boxer	Director	Nov 19 '24	Proposed Sale	159.98	9,682	1,548,931		Nov 19 05:19 PM
Baynes Roy D.	Director	Nov 15 '24	Option Exercise	23.48	37,230	874,177	53,037	Nov 15 09:50 PM
Baynes Roy D.	Director	Nov 15 '24	Sale	146.11	37,230	5,439,565	15,807	Nov 15 09:50 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Nov 15 '24	Sale	146.41	4,728	692,209	185,034	Nov 15 09:50 PM
Sheena Jonathan	CO-FOUNDER	Nov 13 '24	Sale	153.54	20,000	3,070,769	259,772	Nov 15 09:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 13 '24	Sale	156.48	16,300	2,550,628	47,782	Nov 15 09:05 PM
Marcus Gail Boxer	Director	Nov 14 '24	Sale	158.53	2,212	350,672	19,386	Nov 15 09:05 PM
ROY D BAYNES	Director	Nov 15 '24	Proposed Sale	146.11	37,230	5,439,564		Nov 15 04:00 PM
STEVEN L CHAPMAN	Officer	Nov 15 '24	Proposed Sale	146.41	4,728	692,209		Nov 15 04:00 PM
Marcus Gail Boxer	Director	Nov 14 '24	Proposed Sale	158.53	2,212	350,672		Nov 14 05:37 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 11 '24	Option Exercise	5.40	130,000	701,389	2,470,684	Nov 13 09:50 PM
Rabinowitz Matthew	EXECUTIVE CHAIRMAN	Nov 12 '24	Option Exercise	5.40	10,000	53,953	2,480,684	Nov 13 09:50 PM
Sheena Jonathan	Director	Nov 13 '24	Proposed Sale	154.86	36,300	5,621,395		Nov 13 10:27 AM
Sheena Jonathan	CO-FOUNDER	Nov 08 '24	Sale	130.77	3,000	392,306	55,932	Nov 12 09:05 PM
Sheena Jonathan	CO-FOUNDER	Nov 08 '24	Sale	130.80	2,700	353,165	279,772	Nov 12 09:05 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 31 '24	Sale	126.45	1,866	235,956	68,851	Nov 01 09:35 PM
MICHAEL BURKES BROPHY	Officer	Oct 31 '24	Proposed Sale	126.73	1,866	236,478		Oct 31 04:27 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 28 '24	Sale	118.21	1,057	124,948	206,027	Oct 30 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 28 '24	Sale	118.21	1,196	141,380	110,695	Oct 30 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 28 '24	Sale	118.21	929	109,818	113,136	Oct 30 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 28 '24	Sale	118.21	3,960	468,114	189,762	Oct 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 28 '24	Sale	118.21	1,238	146,345	71,471	Oct 30 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 29 '24	Sale	119.93	754	90,427	70,717	Oct 30 09:35 PM
MICHAEL BURKES BROPHY	Officer	Oct 29 '24	Proposed Sale	120.71	754	91,015		Oct 29 04:22 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 24 '24	Sale	119.19	914	108,940	73,400	Oct 25 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 25 '24	Sale	118.81	691	82,098	72,709	Oct 25 09:35 PM
MICHAEL BURKES BROPHY	Officer	Oct 24 '24	Proposed Sale	118.65	1,605	190,433		Oct 24 04:21 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 21 '24	Sale	120.76	294	35,503	112,147	Oct 23 09:35 PM
Moshkevich Solomon	PRESIDENT, CLINICALDIAGNOSTICS	Oct 22 '24	Sale	120.07	256	30,738	111,891	Oct 23 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 21 '24	Sale	120.76	342	41,299	114,264	Oct 23 09:35 PM
Fesko John	PRESIDENT, CHIEF BUS. OFFICER	Oct 22 '24	Sale	120.07	199	23,894	114,065	Oct 23 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 23 '24	Sale	119.09	496	59,068	74,314	Oct 23 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 21 '24	Sale	120.76	467	56,394	207,433	Oct 22 09:35 PM
RABINOWITZ DANIEL	SEC. AND CHIEF LEGAL OFFICER	Oct 22 '24	Sale	120.07	349	41,904	207,084	Oct 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 21 '24	Sale	120.76	1,709	206,375	194,615	Oct 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 22 '24	Sale	120.07	893	107,223	193,722	Oct 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 21 '24	Sale	120.76	608	73,420	74,014	Oct 22 09:35 PM
Brophy Michael Burkes	CHIEF FINANCIAL OFFICER	Oct 22 '24	Sale	120.07	454	54,512	73,560	Oct 22 09:35 PM
Chapman Steven Leonard	CEO AND PRESIDENT	Oct 15 '24	Sale	130.40	4,523	589,797	191,163	Oct 17 09:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NTRA

Natera Inc

Upgrade your FINVIZ experience